Trevena (NASDAQ:TRVN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Saturday. They currently have a $2.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target points to a potential upside of 14.29% from the stock’s current price.
According to Zacks, “Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company’s product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania. “
TRVN has been the subject of several other reports. Needham & Company LLC decreased their price objective on Trevena from $9.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 8th. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Trevena in a report on Wednesday, November 8th. Barclays downgraded Trevena from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $15.00 to $2.50 in a report on Monday, October 16th. Finally, Oppenheimer reaffirmed a “buy” rating and set a $5.00 price target on shares of Trevena in a report on Monday, November 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $8.05.
Trevena (NASDAQ:TRVN) traded up $0.02 during mid-day trading on Friday, hitting $1.75. The stock had a trading volume of 445,438 shares, compared to its average volume of 1,107,701. The firm has a market capitalization of $107.78, a P/E ratio of -1.06 and a beta of -0.58. Trevena has a 1-year low of $1.35 and a 1-year high of $8.00. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.92 and a quick ratio of 4.92.
Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.06. During the same period last year, the company earned ($0.57) earnings per share. equities research analysts expect that Trevena will post -1.23 EPS for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in TRVN. Dimensional Fund Advisors LP lifted its holdings in Trevena by 528.5% in the second quarter. Dimensional Fund Advisors LP now owns 711,615 shares of the biopharmaceutical company’s stock valued at $1,637,000 after acquiring an additional 598,383 shares during the period. Vanguard Group Inc. lifted its holdings in Trevena by 15.0% in the second quarter. Vanguard Group Inc. now owns 1,822,103 shares of the biopharmaceutical company’s stock valued at $4,191,000 after acquiring an additional 238,089 shares during the period. Northern Trust Corp lifted its holdings in Trevena by 15.8% in the second quarter. Northern Trust Corp now owns 572,662 shares of the biopharmaceutical company’s stock valued at $1,318,000 after acquiring an additional 77,934 shares during the period. Northpointe Capital LLC lifted its holdings in Trevena by 5.0% in the third quarter. Northpointe Capital LLC now owns 1,283,025 shares of the biopharmaceutical company’s stock valued at $3,272,000 after acquiring an additional 61,546 shares during the period. Finally, State Street Corp lifted its holdings in Trevena by 8.3% in the second quarter. State Street Corp now owns 768,249 shares of the biopharmaceutical company’s stock valued at $1,767,000 after acquiring an additional 58,895 shares during the period. 56.10% of the stock is owned by institutional investors.
WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of US & international copyright legislation. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/20/trevena-trvn-stock-rating-lowered-by-zacks-investment-research.html.
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.